| Viral P Mehta, MD | |
|
201 E Grover St, Shelby, NC 28150-3917 | |
| (980) 487-3678 | |
| Not Available |
| Full Name | Viral P Mehta |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 20 Years |
| Location | 201 E Grover St, Shelby, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922207877 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2007-01161 (North Carolina) | Secondary |
| 207R00000X | Internal Medicine | 2007-01161 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Atrium Health Union | Monroe, NC | Hospital |
| Mcleod Regional Medical Center-pee Dee | Florence, SC | Hospital |
| Musc Health Florence Medical Center | Florence, SC | Hospital |
| Memorial Mission Hospital And Asheville Surgery Ce | Asheville, NC | Hospital |
| Carolinas Medical Center-northeast | Concord, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carolinas Physicians Network Inc | 3375449655 | 1613 |
| Hospital Physician Services - Southeast Professional Corporation | 5597774554 | 640 |
| Musc Community Physicians | 6507260668 | 698 |
| Mcleod Regional Medical Center Of The Pee Dee, Inc | 7416851852 | 218 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | The Mcdowell Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699772657 PECOS PAC ID: 2264343979 Enrollment ID: O20031107000487 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Caromont Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356314272 PECOS PAC ID: 3577476258 Enrollment ID: O20031201000070 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Carolinas Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477878890 PECOS PAC ID: 3375449655 Enrollment ID: O20031219000455 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Transylvania Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174549208 PECOS PAC ID: 4880592427 Enrollment ID: O20031222000135 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Henderson County Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447444559 PECOS PAC ID: 8123938115 Enrollment ID: O20040611001396 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Inpatient Consultants Of North Carolina Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669422846 PECOS PAC ID: 5991720591 Enrollment ID: O20051012001172 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Blue Ridge Regional Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679570840 PECOS PAC ID: 0648181966 Enrollment ID: O20060410000335 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Angel Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497753651 PECOS PAC ID: 9638253297 Enrollment ID: O20090312000353 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Columbus Regional Health Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508001009 PECOS PAC ID: 6608924931 Enrollment ID: O20090424000511 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | The Charlotte-mecklenburg Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669738829 PECOS PAC ID: 2961310685 Enrollment ID: O20100309000605 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Mission Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114150190 PECOS PAC ID: 0749326106 Enrollment ID: O20100313000054 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Hospital Physician Services - Southeast Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760410385 PECOS PAC ID: 5597774554 Enrollment ID: O20100512000495 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Highlands-cashiers Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851685051 PECOS PAC ID: 6103096433 Enrollment ID: O20110824000544 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Mission Health Community Multispecialty Providers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457719130 PECOS PAC ID: 9537468574 Enrollment ID: O20160426001883 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Entity Name | Musc Community Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841878006 PECOS PAC ID: 6507260668 Enrollment ID: O20210811002388 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Viral P Mehta, MD Po Box 19305, Charlotte, NC 28219-9305 Ph: () - | Viral P Mehta, MD 201 E Grover St, Shelby, NC 28150-3917 Ph: (980) 487-3678 |
News Archive
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
LifePoint Hospitals, Inc. announced today the pricing of $400 million in aggregate principal amount of its 6.625% Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.
› Verified 8 days ago
Renee B. Melton-smith, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 807 Schenck St, Ste 2, Shelby, NC 28150 Phone: 980-487-2540 | |
Kyle Anthony Aldinger, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 711 N Dekalb St, Shelby, NC 28150 Phone: 704-482-1482 Fax: 704-480-6012 | |
Osaguona Osa, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 E Grover St, Shelby, NC 28150 Phone: 980-487-3678 Fax: 980-487-2222 | |
Paul Brent Ferrell, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 711 N Dekalb St, Shelby, NC 28150 Phone: 704-482-1482 Fax: 704-480-6012 | |
Aamir Iqbal, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 711 N Dekalb St, Shelby, NC 28150 Phone: 704-482-1482 | |
Forrest Leigh Thompson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 E Grover St, Shelby, NC 28150 Phone: 980-487-2600 | |
Donnielle Lynn Green, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 951 Wendover Height Dr, Shelby, NC 28150 Phone: 704-487-4677 Fax: 704-887-6450 |